Table 2.

The clinical measures of GAA-FGF14 positive and negative patients with MSA-c.

	GAA-FGF14 positive MSA-c (n = 4)	GAA-FGF14 negative MSA-c (n = 297)	p value
Sex			0.708a
Male	2 (50%)	176 (59%)
Female	2 (50%)	121 (41%)
Age at onset/years	55.5 (48–68)	53 (36–71)	0.457b
Duration/years	3 (3–3)	2 (0.5–8)	0.088b
UMSARS Ⅰ score	13.5 (7–25)	16 (5–44)	0.257c
UMSARS Ⅱ score	13.5 (9–21)	15 (5–48)	0.294c
Rate of disease progression	9.5 (5.7–14)	16 (2.4–67)	0.054b

Quantitative variables were presented as median and range.

^aPearson's chi-square test.

^bWilcoxon rank sum test.

^cAnalysis of covariance (ANCOVA). $\text{Rate}\text{of}\text{disease}\text{progression}=\frac{\text{UMSARS}\text{I}+\text{UMSARS}\text{II}}{\text{Duration}(\text{years})}$.